ライフサイエンスコーパス: cannabinoid receptor

1 t affinity for the centrally expressed CB(1) cannabinoid receptor.

2 endogenous allosteric enhancer of the CB(1) cannabinoid receptor.

3 1 and CB2 ligands and has been proposed as a cannabinoid receptor.

4 PR55 has been postulated to serve as a novel cannabinoid receptor.

5 y arachidonic acid, which has no activity on cannabinoid receptors.

6 nvestigate PPAR agonists for activity at the cannabinoid receptors.

7 rol (2-AG), and controls its availability at cannabinoid receptors.

8 , which releases 2-AG, and presynaptic CB(1) cannabinoid receptors.

9 e periphery and interact with peripheral CB2 cannabinoid receptors.

10 side effects accompanying agonists of type-1 cannabinoid receptors.

11 er release upon activating presynaptic CB(1) cannabinoid receptors.

12 elective ligands from those interacting with cannabinoid receptors.

13 a therapeutic target along with metabotropic cannabinoid receptors.

14 lammatory pain, which were mediated by CB(1) cannabinoid receptors.

15 ate the accumulation and efficacy of 2-AG at cannabinoid receptors.

16 be high affinity ligands for the CB1 and CB2 cannabinoid receptors.

17 ts of 2-AG are mediated by G-protein-coupled cannabinoid receptors.

18 gement of the enteric nervous system through cannabinoid receptors.

19 es of these SCs retain their activity at the cannabinoid receptors.

20 them (14b) being selective versus classical cannabinoid receptors.

21 rostaglandin synthesis than by activation of cannabinoid receptors.

22 olites of these SCs retain their activity at cannabinoid receptors.

23 ical effects through their interactions with cannabinoid receptors.

24 nists (21) is fully selective versus classic cannabinoid receptors.

25 ound to require intact signaling through CB2 cannabinoid receptors.

26 The location of cannabinoid receptor 1 (CB(1)) in the retina is known, b

27 Immunohistochemistry for cannabinoid receptor 1 (CB(1)), another marker for CCK-c

28 hin intron 2 of the CNR1 gene, which encodes cannabinoid receptor 1 (CB(1)), have been associated wit

29 The cannabinoid receptor 1 (CB(1)R) is required for body wei

30 in-2-yl)phenyl)urea (PSNCBAM-1, 2) bound the cannabinoid receptor 1 (CB1) and antagonized G protein c

31 gated the effect of treatment of mice with a cannabinoid receptor 1 (CB1) antagonist on Diet-Induced

32 Cannabinoid receptor 1 (CB1) antagonists are potentially

33 Inhibition of cannabinoid receptor 1 (CB1) has shown efficacy in reduc

34 Agonists of the cannabinoid receptor 1 (CB1) have been suggested as poss

35 Antagonists of cannabinoid receptor 1 (CB1) have potential for the trea

36 al and motivational states via activation of cannabinoid receptor 1 (CB1) in the brain.

37 The cannabinoid receptor 1 (CB1) is a G protein-coupled rece

38 The cannabinoid receptor 1 (CB1) is an inhibitory G protein-

39 The cannabinoid receptor 1 (CB1) is the principal target of

40 Cannabinoid receptor 1 (CB1) is the principal target of

41 We show that anxiolysis depends on intact cannabinoid receptor 1 (CB1) receptors on forebrain GABA

42 The cannabinoid receptor 1 (CB1), a member of the class A G

43 diated by the endocannabinoid anandamide and cannabinoid receptor 1 (CB1), was significantly attenuat

44 ids modulate intestinal permeability through cannabinoid receptor 1 (CB1).

45 nt on metabotropic glutamate receptor 5, and cannabinoid receptor 1 (CB1).

46 is completely abolished in the presence of a cannabinoid receptor 1 (CB1R) antagonist and in mice lac

47 n-coupled receptor (GPCR) 55 (GPR55) and the cannabinoid receptor 1 (CB1R) are co-expressed in many t

48 rincipal cortical neurons leads to defective cannabinoid receptor 1 (CB1R) dependent synaptic plastic

49 Cannabinoid receptor 1 (CB1R) is critical for the centra

50 nnabinoid system (ECS) through antagonism of cannabinoid receptor 1 (CB1R) reduces food intake and im

51 protein-coupled receptors (GPCRs), including cannabinoid receptor 1 (CB1R), desensitization has been

52 Here by studying the cannabinoid receptor 1 (CB1R), we identify ligand-specif

53 interactor with the intracellular region of Cannabinoid Receptor 1 (CB1R, also known as Cnr1 or CB1)

54 n, but not endodermal specification: loss of cannabinoid receptor 1 (cnr1) and cnr2 activity leads to

55 Treatment of ob/ob (obese) mice with a cannabinoid receptor 1 (Cnr1) antagonist reduces food in

56 se 1 (DNMT1), delta-opioid receptor (OPRD1), cannabinoid receptor 1 (CNR1), and catechol-o-methyltran

57 Levels of cannabinoid receptor 1 (CNR1), DNA (cytosine-5-)-methylt

58 nt brain functions and it is mediated by the cannabinoid receptor 1 (CNR1), which is encoded by the C

59 Here, we show that upregulation of the cannabinoid receptor 1 (Cnr1/Cb1) by PAX3-FOXO1 in mouse

60 ciency is not fully abrogated by the inverse cannabinoid receptor 1 agonist SR141716 (Rimonabant) sug

61 Mixed cannabinoid receptor 1 and 2 (CB1 and CB2) agonists such

62 M PPARalpha antagonist GW6471, but not 1 muM cannabinoid receptor 1 antagonist SR141716A, produced a

63 In contrast, AM251 (10 mum), a cannabinoid receptor 1 antagonist, did not impair visual

64 augmentation of AEA signaling and via direct cannabinoid receptor 1 stimulation with Delta(9)-tetrahy

65 The endocannabinoid system comprises cannabinoid receptors 1 and 2 (CB1 and CB2), their endog

66 NADA is also an agonist of cannabinoid receptors 1 and 2.

67 Cannabinoid receptor-1 (CB(1)) blockade improves insulin

68 Inhibition of the cannabinoid receptor-1 (CB1) by the antagonist rimonaban

69 GLP-1R agonism, cannabinoid receptor-1 (CB1-R) antagonism, or vehicle wa

70 teration of glucose homeostasis dependent on cannabinoid receptor-1 (CB1R) activation.

71 itron emission tomography scan each with the cannabinoid receptor-1 (CB1R) selective radiotracer [(11

72 Signaling through cannabinoid receptor 2 (CB(2)) dampens immune activation

73 tant regulator of immune responses, with the cannabinoid receptor 2 (CB2) and its principle ligand 2-

74 ous work demonstrated that mice deficient in cannabinoid receptor 2 (CB2) have decreased numbers of M

75 t CXCR4 can form an induced heterodimer with cannabinoid receptor 2 (CB2) in human breast and prostat

76 Cannabinoid receptor 2 (CB2) is highly expressed in immu

77 Cannabinoid receptor 2 (CB2) is predominantly expressed

78 We investigated the role of the cannabinoid receptor 2 (CB2), an important modulator of

79 we uncover a role for AEA and its receptor, cannabinoid receptor 2 (CB2), in the regulation of immun

80 ypical GPCR present on these cells, i.e. the cannabinoid receptor 2 (CB2), was selected for pharmacol

81 Administration of cannabinoid receptor 2 (CB2R) agonists in inflammatory a

82 icle by Rom et al which shows that selective cannabinoid receptor 2 activation in leukocytes decrease

83 t time, that transient administration of the cannabinoid receptor 2 antagonist AM630 (10 mg/kg) or in

84 Pretreatment of anterior segments with 1 muM cannabinoid receptor 2 antagonist SR144528 and 1 muM PPA

85 The discovery of functional cannabinoid receptors 2 (CB2Rs) in brain suggests a pote

86 perties by virtue of its ability to activate cannabinoid receptor-2 (CB-2) expressed on immune cells.

87 nflammatory IL-10 cytokines, in part through cannabinoid receptor-2 activation.

88 1 receptor-dependent manner--suggesting that cannabinoid receptor activation modifies timing behavior

89 e molecular cascade coupling agonist-induced cannabinoid receptor activation to insulin release remai

90 glial Slit2 production on cell-type-specific cannabinoid receptor activation.

91 sired psychoactive effects of neuronal CB(1) cannabinoid receptor activation.

92 ium-activated potassium (SK) channel and CB1 cannabinoid receptor activation.

93 ture EPSCs (mEPSCs) attributable to enhanced cannabinoid receptor activity, decreased mEPSC amplitude

94 elf-administration (SA), using the synthetic cannabinoid receptor agonist WIN55,212-2 (WIN), in order

95 The cannabinoid receptor agonist WIN55212-2 (10-30 ng/side),

96 The cannabinoid receptor agonist, Delta(9)-tetrahydrocannabi

97 Treatment of neonates with the cannabinoid receptor agonist, WIN 55,212-2 (WIN), reduce

98 of several compounds as potent and selective cannabinoid receptor agonists (20, hCB(2)K(i) = 2.5 nM,

99 esent study demonstrates that the endogenous cannabinoid receptor agonists 2-arachidonoylglycerol (2-

100 Notably, cannabinoid receptor agonists as well as inhibitors of e

101 Cannabinoid receptor agonists have gained attention as p

102 ion of central nervous system (CNS)-excluded cannabinoid receptor agonists to test the hypothesis tha

103 55 (GPR55) has been proposed as a potential cannabinoid receptor, although controversy remains on it

104 full selectivity for the nonpsychotropic CB2 cannabinoid receptor and with efficacy in inducing death

105 describe the subcellular localization of CB1 cannabinoid receptors and eCB synthetic machinery at glu

106 an endogenous signaling system consisting of cannabinoid receptors and endogenous cannabinoids as wel

107 n anandamide, is the true natural ligand for cannabinoid receptors and the key endocannabinoid involv

108 gnaling system, comprising G protein-coupled cannabinoid receptors and their endogenous lipid-derived

109 veral new potential mechanisms involving the cannabinoid receptors and transient receptor potential c

110 transporter 3 (VGLUT3)/cholecystokinin/CB(1) cannabinoid receptor(+) and neuropeptide Y(+) local-circ

111 metabotropic glutamate receptors, and CB(1) cannabinoid receptors) and one ionotropic receptor with

112 , as shown by its failure to bind to the CB1 cannabinoid receptor, and has no activity in CB2-deficie

113 GPR55 is a putative cannabinoid receptor, and l-alpha-lysophosphatidylinosit

114 mpounds, evaluated on both hCB(1) and hCB(2) cannabinoid receptors, and assessed 11 of them in the TN

115 t (LA) but not affected by administration of cannabinoid receptor antagonist (AM251).

116 A cannabinoid receptor antagonist significantly increased

117 Local infusion of the CB(1)-cannabinoid receptor antagonist, rimonabant, into the du

118 This burst firing was suppressed by a cannabinoid receptor antagonist.

119 f the acetaminophen metabolite AM 404 and of cannabinoid receptor antagonists as well as data from ti

120 eatment with the peripherally restricted CB1 cannabinoid receptor antagonists, AM6546 and URB447.

121 Cannabinoid receptors are functionally operant at both g

122 rs are present in the nervous system and CB2 cannabinoid receptors are in the immune system, recent e

123 Cannabinoid receptors are located on cholinergic neurons

124 obilization and consequent activation of CB1 cannabinoid receptors are necessary and sufficient to ex

125 The most abundant cannabinoid receptors are the CB1 cannabinoid receptors;

126 lucose-feedback sensor) and CNR2 (encoding a cannabinoid receptor) as central effectors of B-lymphoid

127 nfirm structures of three mutants of the CB1 cannabinoid receptor associated with different functions

128 consequent reduction in basal stimulation of cannabinoid receptors augmented GABA release probability

129 d differences in regional benzodiazepine and cannabinoid receptor binding site expression.

130 CB cannabinoid receptor blockade prevented these effects.

131 Type 1 cannabinoid receptor blockers increase high-density lipo

132 oposed that OX(1) orexin receptors and CB(1) cannabinoid receptors can form heteromeric complexes, wh

133 potential recordings has shown that central cannabinoid receptor (cannabinoid receptor type 1) agoni

134 noid ligands on stability of the recombinant cannabinoid receptor CB(2), and provide guidelines for p

135 es elicited by central administration of the cannabinoid receptor (CB(1)R) agonist WIN55,212-2 in con

136 tegration between the Galphai-coupled type I cannabinoid receptor (CB(1)R) and the Galphaq-coupled AT

137 egulators of MC biology, we investigated how cannabinoid receptor (CB) 1 signaling affects human muco

138 Because activation of CB(1) cannabinoid receptors (CB(1)R) induces vasodilation and

139 endocannabinoid activation of hepatic CB(1) cannabinoid receptors (CB(1)R), which increases lipogene

140 rast, there is little knowledge about type-2 cannabinoid receptors (CB(2)Rs) in the CNS.

141 bitory effects demonstrated by activation of cannabinoid receptors (CB) on cancer proliferation and m

142 o adrenergic receptors alpha1 and alpha2 and cannabinoid receptor CB1, but had no effect in nuclear r

143 An allosteric ligand for the cannabinoid receptor CB1, Org 27569, exhibits an intrigu

144 oylethanolamine (anandamide), which activate cannabinoid receptors CB1 and CB2 in the nervous system

145 Agonism of the cannabinoid receptors CB1/2 significantly reduces IOP cl

146 Modulation of type 1 cannabinoid receptor (CB1) activity has been touted as a

147 sic activity and produced cross-tolerance to cannabinoid receptor (CB1) agonists in mice, effects tha

148 thanolamine), was shown to bind to the human cannabinoid receptor (CB1) and activate intracellular si

149 uronal cell loss in HD, levels of the type 1 cannabinoid receptor (CB1) decrease in the basal ganglia

150 long (D2L) switches the signaling of type 1 cannabinoid receptor (CB1) from Galphai to Galphas, a pr

151 Type 1 cannabinoid receptor (CB1) is the principal mediator of

152 term, plasticity of GABA release from type 1 cannabinoid receptor (CB1)-expressing axons.

153 ng basket cells, axoaxonic cells, and type 1 cannabinoid receptor (CB1)-expressing basket cells, whic

154 CB1 cannabinoid receptors (CB1) are located at axon terminal

155 19-null animals by the expression of a human cannabinoid receptor, CB1, highlighting the orthology of

156 THC), was isolated in the mid-1960s, but the cannabinoid receptors, CB1 and CB2, and the major endoge

157 Cannabinoid receptors, CB1 and CB2, are therapeutic targ

158 lant psychoactive constituent, activate both cannabinoid receptors, CB1 and CB2.

159 noids are primarily mediated by two types of cannabinoid receptors, CB1 receptors in the nervous syst

160 y human ECs from multiple organs express the cannabinoid receptors CB1R, GPR18, and GPR55, as well as

161 primes the recruitment of beta cells by CB1 cannabinoid receptor (CB1R) engagement.

162 Involvement of the type 1 cannabinoid receptor (CB1R) in the effects of alcohol on

163 s revealed that levels of mGluR1, mGluR5, or cannabinoid receptor (CB1R) were unchanged in Fmr1 KO an

164 but molecular effectors downstream of type-1 cannabinoid receptor (CB1R)-activation remain incomplete

165 us, in vivo inhibition of MAGL induces a CB1 cannabinoid receptor (CB1R)-dependent suppression of inh

166 on terminals that express the primary type 1 cannabinoid receptor (CB1R); 3) binds to CB1R, which inh

167 rebellum of mice with global loss of the CB1 cannabinoid receptor (CB1R, Cb1(-/-) mice) and in mice l

168 Activation of type 1 cannabinoid receptors (CB1R) decreases GABA and glutamat

169 ease of endocannabinoids that bind to type 1 cannabinoid receptors (CB1R) located on synaptic termina

170 s on type 1 orexin receptors (OX1Rs), type 1 cannabinoid receptors (CB1Rs) and diacylglycerol lipase

171 CB1 cannabinoid receptors (CB1Rs) are attractive therapeutic

172 Cannabinoid receptors (CB1Rs) are present in glomeruli o

173 Type 1 cannabinoid receptors (CB1Rs) are widely expressed in th

174 We investigated in mice the role of CB1 cannabinoid receptors (CB1Rs) in memory impairment and s

175 yl-D-aspartate receptors (NMDARs) and type 1 cannabinoid receptors (CB1Rs) induces LTD at the first c

176 beta Cells express CB1 cannabinoid receptors (CB1Rs), and the enzymatic machine

177 engers that, by targeting presynaptic type 1 cannabinoid receptors (CB1Rs), mediate short- and long-t

178 Cannabinoid receptor CB2 (CB2(-/-)) mice were used as a

179 Expression of CB2 cannabinoid receptor (CB2R) and Il1b mRNA was increased

180 at may enhance intravenous SA of THC and the cannabinoid receptor (CBR) agonist CP 55 940 in Old Worl

181 s unknown, as is the potential modulation by cannabinoid receptors (CBRs).

182 control over neuronal activity by activating cannabinoid receptors (CBRs).

183 trate that genetic or chemical inhibition of cannabinoid receptor (Cnr) activity disrupts liver devel

184 s callosum enlargement due to the errant CB1 cannabinoid receptor-containing corticofugal axon spread

185 nyl)ethyl amide (WOBE437) exerted pronounced cannabinoid receptor-dependent anxiolytic, antiinflammat

186 glycerol (2-AG) to regulate certain forms of cannabinoid receptor-dependent signaling in the nervous

187 tein, and the inactivation of DAGLs disrupts cannabinoid receptor-dependent synaptic plasticity and i

188 n the brain of MKO(GFAP) mice does not cause cannabinoid receptor desensitization as previously obser

189 creased social play, but blockade of NAc CB1 cannabinoid receptors did not antagonize the play-enhanc

190 Although genetic variation in the type 1 cannabinoid receptor--encoded by the CNR1 gene--is known

191 pid mediators include endogenous agonists of cannabinoid receptors (endocannabinoids), lipid-amide ag

192 docannabinoid system, comprising CB1 and CB2 cannabinoid receptors, endogenous cannabinoids (endocann

193 The ECS comprises cannabinoid receptors, endogenous cannabinoids (endocann

194 By activating cannabinoid receptors expressed in the central nervous s

195 oids, suggesting that they arise from type 1 cannabinoid receptor-expressing (CB1R+) interneurons - m

196 The cannabinoid receptor full agonist [(R)-(+)-[2,3-dihydro-

197 se data are the first to show alterations in cannabinoid receptor function in the rostral anterior ci

198 re provides an atomic framework for studying cannabinoid receptor function, and will aid the design a

199 ve blockade or inverse agonism of the type 1 cannabinoid receptor has been tested for the improvement

200 In particular, CB(2) cannabinoid receptors have been shown to promote NP prol

201 The cannabinoid receptors have been the targets of intensive

202 Cannabinoid receptors have gained increasing attention a

203 s of regular cannabis users, particularly in cannabinoid receptor-high areas, which are vulnerable to

204 t abundant cannabinoid receptors are the CB1 cannabinoid receptors; however, CB2 cannabinoid receptor

205 ions emerged across regions that are high in cannabinoid receptors (i.e., hippocampus, prefrontal cor

206 G) and anandamide (AEA) activate a canonical cannabinoid receptor in Caenorhabditis elegans and also

207 The function of the CB2 cannabinoid receptor in the brain has long been a matter

208 e potential to interact therapeutically with cannabinoid receptors in addition to its primary PPAR ta

209 ass of lipid-derived mediators that activate cannabinoid receptors in many cells of the body - are ke

210 system (CNS) and the functionality of type-1 cannabinoid receptors in neurons is well documented.

211 The roles of CB1 cannabinoid receptors in regulating neuronal activity ha

212 n of the involvement of endocannabinoids and cannabinoid receptors in skeletal muscle cell differenti

213 social play increased phosphorylation of CB1 cannabinoid receptors in the amygdala.

214 Cannabinoid receptors in the BLA contribute to anxiogene

215 udy reveals a novel cellular function of CB2 cannabinoid receptors in the hippocampus and provides in

216 wledge on the expression and distribution of cannabinoid receptors in the monkey retina, although fur

217 ppetite hormones mediated through endogenous cannabinoid receptors, independent of glucose metabolism

218 uced A-type potassium current (IA) through a cannabinoid receptor-independent mechanism mimicked by a

219 The Cannabinoid Receptor Interacting Protein 1 (Cnrip1) was

220 Cannabinoid receptor interacting protein 1a (CRIP1a) is

221 Cannabinoid receptor-interacting protein 1a (CRIP1a) bin

222 vidence for marked functional selectivity of cannabinoid receptor internalization.

223 The CB(1) cannabinoid receptor is the major molecular target of en

224 forms of LTD were completely absent in CB(1) cannabinoid receptor knock-out mice, whereas pharmacolog

225 s identified as an example of a new class of cannabinoid receptor ligand and allosteric modulator, wi

226 he present study demonstrates that mammalian cannabinoid receptor ligands activate a conserved cannab

227 Here we profile a number of cannabinoid receptor ligands and provide evidence for ma

228 To study cannabinoid receptor ligands, we have developed a novel

229 t enhancement of anandamide signaling at CB1 cannabinoid receptors localized on sensory nerve endings

230 strate that selective blockade of peripheral cannabinoid receptors may be a novel successful therapeu

231 avioral studies in mice, we demonstrate that cannabinoid receptors mediate acute anxiolysis and analg

232 By discussing the mechanisms of cannabinoid receptor-mediated signaling events at critic

233 In our search for new cannabinoid receptor modulators, we describe herein the

234 ovalent probes with high affinities for both cannabinoid receptors, namely, the electrophilic isothio

235 CB1 cannabinoid receptors on neurons and CB2 cannabinoid receptors on microglia.

236 sion and neuroinflammation by activating CB1 cannabinoid receptors on neurons and CB2 cannabinoid rec

237 ized by their strong expression of the CB(1) cannabinoid receptor, oval/round soma, apical nucleus, a

238 ic and pharmacological manipulation of CB(1) cannabinoid receptors permanently alters cholinergic pro

239 relative to age-matched controls, and CB(1) cannabinoid receptor-positive presynapses engulf amyloid

240 ating near senile plaques and apposing CB(1) cannabinoid receptor-positive presynapses.

241 monoacylglycerol lipase accumulates in CB(1) cannabinoid receptor-positive presynapses.

242 associated metabolic enzymes, together with cannabinoid receptors, predominantly the cannabinoid CB1

243 tative morphometry showed that overall CB(1) cannabinoid receptor protein levels in the hippocampi of

244 tion of the GRIN-Sprouty2 interaction to CB1 cannabinoid receptor regulation of FGF receptor signalin

245 ase of GABA release upon activation of these cannabinoid receptors remain elusive.

246 Notably, cannabinoid receptors serve as molecular targets for the

247 Studies have shown that disruption of cannabinoid receptor signaling reduces operant responses

248 eCBs) allows for more precise fine-tuning of cannabinoid receptor signaling, thus providing therapeut

249 esponse of cannabinoid-sensitive synapses to cannabinoid receptor stimulation, although it altered so

250 n chemical cross-linking strategy to map the cannabinoid receptor subtype 2 (CB2)-Galphai interface a

251 The activation of cannabinoid receptor subtype 2 (CB2R) prevents acinar ce

252 e hippocampus and provides insights into how cannabinoid receptor subtypes diversify the roles of can

253 Two cannabinoid receptor subtypes, CB1 and CB2, have been id

254 Agonists at cannabinoid receptors, such as the phytocannabinoid Delt

255 th unforeseen opposite allosteric effects on cannabinoid receptors, suggests its potential role in pe

256 Marijuana (MJ) acutely acts on cannabinoid receptors that are found in numerous brain r

257 abinoid system consists of G-protein-coupled cannabinoid receptors that can be activated by cannabis-

258 The CB1 cannabinoid receptor, the main molecular target of endoc

259 The CB1 cannabinoid receptor, the main target of Delta(9)-tetrah

260 ive constituent of cannabis binds to the CB1 cannabinoid receptor, the present study was designed to

261 that determine the sign of the modulation by cannabinoid receptors to differentially regulate excitat

262 wing cell-autonomous 2-AG signaling at CB(1) cannabinoid receptors to persist at atypical locations t

263 neurons and act retrogradely on presynaptic cannabinoid receptors to potentiate the locomotor freque

264 the CB1 cannabinoid receptors; however, CB2 cannabinoid receptors, transient receptor potential chan

265 Cannabinoid receptor transmission strongly influences em

266 Cannabinoid receptor type 1 (CB(1)) blockade with the ce

267 proposed to be an endogenous agonist for the cannabinoid receptor type 1 (CB(1)).

268 tivity of peripheral tissues are mediated by cannabinoid receptor type 1 (CB1) and the central nervou

269 Some inverse agonists of cannabinoid receptor type 1 (CB1) have been demonstrated

270 xiolytic, and neuroprotective efficacies via cannabinoid receptor type 1 (CB1) or type 2 (CB2) or via

271 e evaluated the relationship between in vivo cannabinoid receptor type 1 (CB1) receptor availability

272 mpact of such changes on endocannabinoid and cannabinoid receptor type 1 (CB1)-mediated modulation of

273 with antagonist/inverse agonist activity at cannabinoid receptor type 1 (CB1R) and inhibitory effect

274 The cannabinoid receptor type 1 (CB1R) colocalized with TRPV

275 The presence of the cannabinoid receptor type 1 (CB1R) has been largely docu

276 e potential role of endocannabinoids and the cannabinoid receptor type 1 (CB1R) in neonatal neurodege

277 xpress both OX-A receptor type 1 (OX-1R) and cannabinoid receptor type 1 (CB1R) on the plasma membran

278 CRs: the alpha2A-adrenergic receptor, GABAB, cannabinoid receptor type 1 (CB1R), and dopamine recepto

279 hibitory synaptic transmission in the PL via cannabinoid receptor type 1 (CB1R)- and 2-arachidonoylgl

280 ved vehicle, arachidonyl-2-chloroethylamide (cannabinoid receptor type 1 [CB(1) ] agonist), JWH-015 (

281 ng acute hippocampal slices, and hippocampal cannabinoid receptor type 1 and brain-derived neurotroph

282 is factor (TNF)-induced transcription of the cannabinoid receptor type 1 gene in primary fetal striat

283 fatty acid amide hydrolase(-/-) mice, and in cannabinoid receptor type 1(-/-) (CB1-/-) and cannabinoi

284 has shown that central cannabinoid receptor (cannabinoid receptor type 1) agonists decrease the power

285 e downregulation of brain cannabinoid CB(1) (cannabinoid receptor type 1) receptors after chronic exp

286 iking cells, but not interneurons expressing cannabinoid receptor type 1, resulting in the disruption

287 The cannabinoid receptor type 2 (CB2) is a class A GPCR that

288 receptor type 1 [CB(1) ] agonist), JWH-015 (cannabinoid receptor type 2 [CB(2) ] agonist), and AM630

289 strategy identified thienopyrimidine 12 as a cannabinoid receptor type 2 agonist (hCB2) with moderate

290 Expression of cannabinoid receptor Type 2 was reported in osteoblasts

291 annabinoid receptor type 1(-/-) (CB1-/-) and cannabinoid receptor type 2(-/-) (CB2-/-).

292 compound binds to CB1 more selectively than cannabinoid receptor type 2, with a Ki value of 220 nM.

293 Cannabinoid receptor type-1 (CB1) is known to have a sub

294 Cannabinoid receptor type-1 (CB1) plays a crucial role i

295 t subpopulation of NAc FSIs that express the cannabinoid receptor type-1 (CB1).

296 Cannabinoid receptors type 2 (CB2) represent a target wi

297 Potential therapeutic targets include the cannabinoid receptors, type 1 and 2, as well as biosynth

298 CB(1) and CB(2) cannabinoid receptors undergo internalization after sust

299 ocial play behavior, and blockade of BLA CB1 cannabinoid receptors with the antagonist/inverse agonis

300 of dronabinol, a nonselective agonist of the cannabinoid receptor, with those of placebo on colonic m